LYON, France, Dec. 13, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces the release of the first multi-center long-term study of HIFU uses for the treatment of localized prostate cancer. The study’s lead author, Dr. Andreas Blana, concludes that Ablatherm-HIFU efficacy is competitive to currently accepted nonsurgical standards of care, such as radiotherapy, but offers patients milder side effects.
